BRUKINSA is a BTK inhibitor that
was designed to completely block BTK

BRUKINSA® (zanubrutinib) has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The significance of completely blocking BTK on treatment responses has not been established.

BRUKINSA is a prescription
medicine used to treat adults with
Waldenström’s macroglobulinemia (WM).

Bruton’s tyrosine kinase (BTK) is a protein that has been linked to WM.

Patient Support Program

To meet your individual needs, myBeiGene pairs you with a
dedicated Oncology Nurse Advocate who will personalize support
for you and your caregivers during your treatment with
BRUKINSA.

Simplify
access to
BRUKINSA
Educate about
BRUKINSA
Provide
personalized
solutions